Tolerance to amphetamine hypophagia: a real-time depiction of learning to suppress stereotyped movements in the rat

Patient perceptions of lisdexamfetamine as a treatment for binge eating disorder: An exploratory qualitative and quantitative analysis

Lisdexamfetamine (LDX) is the only medication to have gained FDA approval for the treatment of binge eating disorder (BED). LDX treatment is generally effective at reducing binge eating symptoms but is associated with several unwanted side effects. How BED patients perceive the therapeutic efficacy vs. associated side effects of LDX has not been explored. We carried out a thematic analysis of 111 online reviews posted to the website Drugs. com by persons prescribed LDX to treat BED. We also explored how qualitative themes were associated with perceptions of treatment efficacy on a quantitative (1-10 scale) scale. Themes associated with higher efficacy ratings included improved binge eating outcomes, enhanced focus/concentration, as well as weight loss (χ2 tests, p's < 0.05). Lower efficacy ratings were associated with themes that included tolerance to therapeutic effects of LDX, insomnia, return of binge eating in the evening, loss of energy in the afternoon/evening ('crashing'), and weight gain (χ2 tests, p's < 0.05). Limitations of the study include representativeness of the data and self-reported BED diagnosis. Together, these data provide novel insights into individual experiences with LDX as a treatment for BED and their association with perceived efficacy. The causal nature of these relationships should be tested in future studies, as well as any implications for medication adherence.

Choosing between cocaine and sucrose under the influence: testing the effect of cocaine tolerance

RATIONALE

Cocaine use not only depends on the reinforcing properties of the drug, but also on its pharmacological effects on alternative nondrug activities. In animal models investigating choice between cocaine and alternative sweet rewards, the latter influence can have a dramatic impact on choice outcomes. When choosing under cocaine influence is prevented by imposing sufficiently long intervals between choice trials, animals typically prefer the sweet reward. However, when choosing under the drug influence is permitted, animals shift their preference in favor of cocaine.

OBJECTIVES

We previously hypothesized that this preference shift is mainly due to a direct suppression of responding for sweet reward by cocaine pharmacological effects. Here we tested this hypothesis by making rats tolerant to this drug-induced behavioral suppression.

RESULTS

Contrary to our expectation, tolerance did not prevent rats from shifting their preference to cocaine when choosing under the influence.

CONCLUSION

Thus, other mechanisms must be invoked to explain the influence of cocaine intoxication on choice outcomes.

A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia

RATIONALE

The development and validation of animal models of the cognitive impairments of schizophrenia have remained challenging subjects.

OBJECTIVE

We review evidence from a series of experiments concerning an animal model that dissociates between the disruption of attentional capacities during acute illness periods and the cognitive load-dependent impairments that characterize periods of remission. The model focuses on the long-term attentional consequences of an escalating-dosing pretreatment regimen with amphetamine (AMPH).

RESULTS

Acute illness periods are modeled by the administration of AMPH challenges. Such challenges result in extensive impairments in attentional performance and the "freezing" of performance-associated cortical acetylcholine (ACh) release at pretask levels. During periods of remission (in the absence of AMPH challenges), AMPH-pretreated animals' attentional performance is associated with abnormally high levels of performance-associated cortical ACh release, indicative of the elevated attentional effort required to maintain performance. Furthermore, and corresponding with clinical evidence, attentional performance during remission periods is exquisitely vulnerable to distractors, reflecting impaired top-down control and abnormalities in fronto-mesolimbic-basal forebrain circuitry. Finally, this animal model detects the moderately beneficial cognitive effects of low-dose treatment with haloperidol and clozapine that were observed in clinical studies.

CONCLUSIONS

The usefulness and limitations of this model for research on the neuronal mechanisms underlying the cognitive impairments in schizophrenia and for drug-finding efforts are discussed.

Role of instrumental learning in tolerance to cathinone hypophagia

The effects of dl-cathinone on milk intake and motor activity were investigated in bottle- and cannula-fed rats. Acute injections of cathinone produced dose-dependent increases in activity in both groups but only produced decreased intake in bottle-fed rats. With chronic injections, tolerance to the suppression of intake developed in the bottle-fed group, accompanied by decreased activity. After the tolerance phase, switching from bottle to cannula feeding produced further increases in intake, whereas switching from cannula to bottle feeding produced decreased intakes. These results suggest that (a) cathinone suppresses intake by inducing locomotion and stereotypy, which interfere with the appetitive phase of feeding, and (b) tolerance to drug-induced hypophagia involves learning to suppress such movements, as proposed by the instrumental learning model.